BFNH 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-19

• Operating expenses for three months ended March 31, 2026 totaled $117,733 from Board of Director compensation and General and Administrative Expenses, compared to $133,455 for the three months ended March 31, 2025. This decrease in March 31, 2026 compared to the same period ended March 31, 2025 was …

• Net loss for the three months ended March 31, 2026 and 2025 were $102,411 and $934,650, respectively. During the period ending March 31, 2026, the Company recoreded Other Income from a legal settlement in the amount of $15,322.

• As of March 31, 2026, the Company’s assets totaled $6,347 which consisted of Cash. Our total liabilities were $727,301 from accounts payable and accrued expenses, accrued director compensation expenses and amounts due to related parties. As of March 31, 2026, the Company had an accumulated deficit o…

• For the Quarter ended March 31, 2026, net cash provided by operations of $7,088 was the result of a net loss for the period of $102,411, from an increase in Accounts Payables and Accrued Expenses of $8,249, and from an increase in accrued Board of Directors' and Officer Compensation of $101,250.

• For the Quarter ended March 31, 2025, net cash used in operations of $15,215 was the result of a net loss for the period of $934,650, from loss on liability settlement of $802,000, an increase in Accounts Payables and Accrued Expenses of $12,492, and from an increase in accrued Board of Directors' a…

相对上期删除的文字 · 来源:10-Q · 2025-11-19

• Gross Profit for the three months ended September 30, 2025 and 2024 was $-0- .

• Operating expenses for three months ended September 30, 2025 totaled $115,915 from Board of Director compensation and General and Administrative Expenses, compared to $122,024 for the three months ended September 30, 2024. The decrease in September 30, 2025 compared to the same period ended Septembe…

• Nine Months – September 30, 2025 and 2024 - Unaudited Statements

• The Sales Revenue from the Company’s "BioForce Eclipse" vitamin supplement for the nine months ended September 30, 2025 and 2024 were $-0-, Company sold no units of its Bioforce Eclipse" vitamin supplement.

• The Cost of Sales for the nine months ended September 30, 2025 and 2024 were $-0-.

相对上期新增的文字 · 来源:10-Q · 2026-05-19

• Subsequent to the close of the March 31, 2026 quarter, in April 2026, the board of directors received a conversion notice from Nauri Dean Ahmad from whom the Company had borrowed $10,000. In accordance with the loan document between Mr. Ahmad and the Company, Mr Ahmad was entitled to $11,000 in prin…

• Subsequent to the close of the March 31, 2026 quarter, on April 15, 2026, Merle Ferguson, a director of the Company sold his controlling stock interest, approximately 80%, in a private transaction to Nexus Capital Investments, Inc.

相对上期删除的文字 · 来源:10-Q · 2025-11-19

• A related party, on November 10, 2025, provided the Company $10,000 to pay professional service fees and other operational expenses.